ONCODESIGN PRECISION MEDICINE

Highlights Oncodesign Precision Medicine

Equities

ALOPM

FR001400CM63

Real-time Euronext Paris Other stock markets 04:27:49 04/06/2024 pm IST			5-day change	1st Jan Change
1.225 ^EUR	+2.08%		-5.77%	-32.32%

15/05	Oncodesign Precision Medicine and Navigo Proteins GmbH Sign A Strategic Collaboration Agreement for the Research and Development of New Systemic Radiotherapy Agents	CI
25/01	Oncodesign Precision Medicine: fundraising on the horizon	CF

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Oncodesign Precision Medicine and Navigo Proteins GmbH Sign A Strategic Collaboration Agreement for the Research and Development of New Systemic Radiotherapy Agents	15/05	CI
Oncodesign Precision Medicine: fundraising on the horizon	25/01	CF
Eurazeo acquires a stake in Oncodesign Services	23/01	CF
Oncodesign Precision Medicine Société anonyme acquired Zobio B.v.	23/01	CI
Oncodesign Precision Medicine Announces Positive Interim Results of Its Phase 1 Study Evaluating OPM-101 in Healthy Volunteers	02/23/02	CI
Oncodesign Precision Medicine Announces Initiation of Phase I of its RIPK2 Inhibitor ODS-101, aNew Therapeutic Agent for IBD	09/23/09	CI
Edmond de Rothschild Equity Strategies Management III S.à.r.l acquired 61.58% stakes in Oncodesign Precision Medicine Société anonyme from Philippe Genne and other managers and minority shareholder.	19/22/19	CI
Oncodesign Precision Medicine to List Directly on Euronext Access + Paris	05/22/05	MT
Oncodesign Société Anonyme completed the Spin-Off of Oncodesign Precision Medicine Société anonyme.	05/22/05	CI
Oncodesign Société Anonyme completed the Spin-Off of Oncodesign Precision Medicine Société anonyme.	05/22/05	CI
Oncodesign Société Anonyme agreed to Spin-Off Oncodesign Precision Medicine.	28/22/28	CI
Servier Exercises the Exclusive Worldwide License Option of Their Collaboration Program With Oncodesign Precision Medicine on Parkinson's disease	26/22/26	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

+39.41% on our US portfolio vs. 25.67% on the S&P 500 net Total Return

Replicate our performance

fermer